Table 1.
Clinical characteristics of 13 patients receiving personalized immunotherapy
| Patient ID | Age | sex | Primary tumor |
Pathology | Grade | TNM (Stage) |
Metastatic Sites | Prior Therapy | PS* |
|---|---|---|---|---|---|---|---|---|---|
| PW1 | 78 | F | colon | Adenocarcinoma | G3 | T4bN2bM1b (IVB) |
Liver, Peritumor and mesenteric lymph nodes | Surgery | 1 |
| PW2 | 59 | M | colon | Adenocarcinoma | G2 | T3N2bM0 (IIIC) |
Peritumor lymph node | Surgery, Oxaliplatin+capecitabine | 0 |
| PW3 | 33 | F | colon | Adenocarcinoma | G2 | T3N0M1 (IV) |
Liver, Lung, ovary, brain, bone | Oxaliplatin+tegafur, Bevacizumab, Oxaliplatin+capecitabine, Surgery, Irinotecan+5-Fu+calcium folinatc, Apixaban, Oxaliplatin+raltitrexed | 4 |
| PW4 | 52 | F | rectum | Adenocarcinoma | G2 | T3N1aM1 (IV) |
Lung, Peritumor lymph node | Surgery, Bevacizumab+oxaliplatin +capecitabine |
1 |
| PW5 | 72 | F | colon | Adenocarcinoma | G2 | T3N0M1 (IV) |
Liver | Surgery, Oxaliplatin+cetuximab +capecitabine |
1 |
| PW6 | 71 | M | colon | Adenocarcinoma | G2 | T4bN0M1 (IV) |
Liver | Surgery | 1 |
| PW7 | 74 | M | rectum | Adenocarcinoma | G2 | T3N1bM1 (IV) |
Liver, Mesenteric and tumor distal lymph nodes | Surgery, Oxaliplatin+capecitabine | 1 |
| PW8 | 59 | F | colon | Adenocarcinoma | G1-2 | T4aN0M1 (IV) |
Liver | Surgery, Oxaliplatin+cetuximab +capecitabine, Irinotecan+5-Fu +calcium folinatc+cetuximab |
1 |
| PW9 | 49 | F | rectum | Adenocarcinoma | G2 | T3N2M1 (IV) |
Left adnexa, tumor distal lymph nodes | Surgery, Oxaliplatin+capecitabine | 0 |
| PW10 | 66 | F | rectum | Adenocarcinoma | G2 | T4aN1bM1 (IV) |
Uterus, Right fallopian tube, Peritumor lymph nodes | Surgery, Oxaliplatin+capecitabine | 1 |
| PW11 | 57 | M | rectum | Adenocarcinoma | G3 | T4N2M1 (IV) |
Bladder, Peritumor and left internal iliac artery lymph nodes, Napes and omentum majus nodules | Surgery, Oxaliplatin+capecitabine, Bevacizumab, Irinotecan+capecitabine, Bevacizumab+irinotecan+capecitabine, Bevacizumab+raltitrexed, 50 Gy/25 F radiotherapy | 3 |
| PW12 | 89 | M | colon | Adenocarcinoma | G2 | T3N1bM1 (IV) |
Liver, Lung, Mesenteric lymph nodes | Surgery | 2 |
| PW13 | 68 | M | colon | Adenocarcinoma | G3 | T4aN2M1 (IV) |
Peritumor, mesenteric and retroperitoneal lymph nodes | Surgery, Oxaliplatin+capecitabine, Bevacizumab+oxaliplatin +capecitabine, Bevacizumab, Bevacizumab+capecitabine |
1 |
*PS: Performance status: ECOG, Eastern Cooperative Oncology Group.